-
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study 1
Ozaki Y.、 Tokuda E.、 Sagara Y.、 Hara F.、 Sasada S.、 Sawaki M.、 Kanbayashi C.、 Yamanaka T.、 Onishi T.、 Fujiki Y.、 Suto A.、 Takahashi Y.、 Tokunaga E.、 Aruga T.、 Nakamura R.、 Fujisawa T.、 Saji S.、 Iwata H.、 Shien T.
ESMO Open 2025-11-07
-
Postmastectomy radiation therapy for implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese Breast Cancer Society Clinical Practice Guideline 2
Ogita M.、 Sawayanagi S.、 Jinnouchi H.、 Yoshimura M.、 Yamauchi C.、 Sanuki N.、 Hamamoto Y.、 Hirata K.、 Kawamura M.、 Yamamoto Y.、 Saji S.、 Toyama T.
Breast Cancer 2025-11
-
Timing of postmastectomy radiation therapy in two-stage expander/implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese breast cancer society clinical practice guideline 3
Ogita M.、 Sawayanagi S.、 Jinnouchi H.、 Yoshimura M.、 Yamauchi C.、 Sanuki N.、 Hamamoto Y.、 Hirata K.、 Kawamura M.、 Yamamoto Y.、 Saji S.、 Toyama T.
Breast Cancer 2025-11
-
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey 4
NPJ Breast Cancer 2025-10-24
-
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer 5
Burstein HJ、 Curigliano G.、 Gnant M.、 Loibl S.、 Regan MM、 Loi S.、 Denkert C.、 Poortmans P.、 Cameron D, Thurlimann B.、 Weber WP、 Panelists of the、 St. Gallen International、 Breast Cancer Consensus
Ann Oncol 2025-10-08
-
Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese national clinical database-breast cancer registry 6
Ogita M.、 Kumamaru H.、 Kubo M.、 Kinukawa N.、 Niikura N.、 Saji S.、 Toi M.
Breast 2025-10
-
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26) 7
Bando H.、 Ueda A.、 Terata K.、 Doi M.、 Nagai SE、 Hattori M.、 Watanabe K.、 Tamura N.、 Futamura M.、 Koizumi K.、 Niikura N.、 Miyaji T.、 Muramatsu Y.、 Xu L.、 Masuda N.、 Saji S.
Breast Cancer 2025-09
-
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial 8
Shien T.、 Hara F.、 Aogi K.、 Yanagida Y.、 Tsuneizumi M.、 Yamamoto N.、 Matsumoto H.、 Suto A.、 Watanabe K.、 Harao M.、 Kanbayashi C.、 Itoh M.、 Kadoya T.、 Anan K.、 Maeda S.、 Sasaki K.、 Ogawa G.、 Saji S.、 Fukuda H.、 Iwata H.、 JCOG Breast Cancer Study Group
Br J Cancer 2025-09
-
Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan 9
Miyashita M.、 Kumamaru H.、 Hayashi N.、 Kimura F.、 Yamamoto H.、 Niikura N.、 Sagara Y.、 Jinno H.、 Toi M.、 Saji S.
Breast Cancer 2025-09
-
Comparison of Effectivity and Safety of Olanzapine and Mirtazapine on Cancer-Associated Anorexia and Cachexia in Advanced Oral Cavity Cancer Patients: Prospective, Comparative, Interventional Study 10
Singhal Y.、 Pingoliya SK、 Gaurav R P.、 Saji S.、 Sharma A.
J Pain Palliat Care Pharmacother 2025-09
-
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer 11
Yoshinami T.、 Takano Y.、 Ozaki Y.、 Kajiwara Y.、 Yamamoto M.、 Watanabe KI、 Tsukabe M.、 Fujisawa F.、 Nagai SE、 Shibata N.、 Oshiro C.、 Bando H.、 Tsunoda N.、 Yamagami K.、 Koizumi K.、 Takada M.、 Toriguchi N.、 Sekine N.、 Kawaguchi T.、 Saji S.、 Sagara Y.、 Morita S.、 Masuda N.
Breast Cancer 2025-09
-
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy 12
Early Breast Cancer Trialists' Collaborative Group、 EBCTCG
Lancet 2025-08-09
-
Risk factors for early mortality among patients with gastrointestinal malignancy in the C-CAT database. 13
Suzuki R.、 Shimizu H.、 Sato K.、 Asama H.、 Ohira R.、 Sugimoto M.、 Saito R.、 Okano M.、 Kimura-Tsuchiya R.、 Satio M.、 Saji S.、 Takagi T.、 Ohira H.
International journal of clinical oncology 2025-08
-
Advancing equitable access to innovation in breast cancer 14
O'Reilly S.、 Luis IV、 Adam V.、 Razis ED、 Urruticoechea A.、 Arahmani A.、 Carrasco E.、 Chua BH、 Bliss J.、 Straehle C.、 Goulioti T.、 Lindholm B.、 Werustsky G.、 Brain E.、 Bedard PL、 Curigliano G.、 Loi S.、 Saji S.、 Cameron D.
NPJ Breast Cancer 2025-07-10
-
Advancing equitable access to innovation in breast cancer. 15
O'Reilly S.、 Luis IV、 Adam V.、 Razis ED、 Urruticoechea A.、 Arahmani A.、 Carrasco E.、 Chua BH、 Bliss J.、 Straehle C.、 Goulioti T.、 Lindholm B.、 Werustsky G.、 Brain E.、 Bedard PL、 Curigliano G.、 Loi S.、 Saji S.、 Cameron D.
NPJ breast cancer 2025-07-10
-
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 16
Mittendorf EA、 Assaf ZJ、 Harbeck N.、 Zhang H.、 Saji S.、 Jung KH、 Hegg R.、 Koehler A.、 Sohn J.、 Iwata H.、 Telli ML、 Ferrario C.、 Punie K.、 Qamra A.、 Dieterich M.、 Xu Y.、 Liste-Hermoso M.、 Shearer-Kang E.、 Molinero L.、 Chui SY、 Barrios CH
Nat Med 2025-07
-
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status. 17
Konishi T.、 Kumamaru H.、 Niikura N.、 Sagara Y.、 Miyashita M.、 Iwamoto T.、 Sanuki N.、 Tanakura K.、 Nagahashi M.、 Yoshida M.、 Kawashima M.、 Kinoshita T.、 Sasada S.、 Kinukawa N.、 Saji S.、 Ishida T.、 Taira N.
Breast cancer (Tokyo, Japan) 2025-07
-
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status(タイトル和訳中) 18
Konishi Takaaki、 Kumamaru Hiraku、 Niikura Naoki、 Sagara Yasuaki、 Miyashita Minoru、 Iwamoto Takayuki、 Sanuki Naoko、 Tanakura Kenta、 Nagahashi Masayuki、 Yoshida Masayuki、 Kawashima Masahiro、 Kinoshita Takayuki、 Sasada Shinsuke、 Kinukawa Naoko、 Saji Shigehira、 Ishida Takanori、 Taira Naruto
Breast Cancer 2025-07
-
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer 19
Yoshinami T.、 Takano Y.、 Ozaki Y.、 Kajiwara Y.、 Yamamoto M.、 Watanabe KI、 Tsukabe M.、 Fujisawa F.、 Nagai SE、 Shibata N.、 Oshiro C.、 Bando H.、 Tsunoda N.、 Yamagami K.、 Koizumi K.、 Takada M.、 Toriguchi N.、 Sekine N.、 Kawaguchi T.、 Saji S.、 Sagara Y.、 Morita S.、 Masuda N.
Breast Cancer 2025-07
-
Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry. 20
Taji T.、 Kumamaru H.、 Kataoka Y.、 Iijima K.、 Suwa H.、 Ishiguro H.、 Taira N.、 Ishida T.、 Saji S.
Breast (Edinburgh, Scotland) 2025-06
